Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes
Pharmacological Reviews · 2024
DOI: 10.1124/pharmrev.123.000938 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Reviews, 2024. Verfasst von K T Babalola und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Center for Convergent Bioscience and Medicine (CCBM) (K.T.B., M.A., R.G., M.N.V.R.K.), Division of Translational Science and Medicine, College of…. Hauptthemen laut MEDLINE: Drug Delivery Systems, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
The role of advanced drug delivery strategies in drug repositioning and minimizing drug attrition rates, when applied early in drug discovery, is poised to increase the translational impact of various therapeutic strategies in disease prevention and treatment. In this context, drug delivery to the lymphatic system is gaining prominence not only to improve the systemic bioavailability of various pharmaceutical drugs but also to target certain specific diseases associated with the lymphatic system. Although the role of the lymphatic system in lupus is known, very little is done to target drugs to yield improved clinical benefits. In this review, we discuss recent advances in drug delivery strategies to treat lupus, the various routes of drug administration leading to improved lymph node bioavailability, and the available technologies applied in other areas that can be adapted to lupus treatment. Moreover, this review also presents some recent findings that demonstrate the promise of lymphatic targeting in a preclinical setting, offering renewed hope for certain pharmaceutical drugs that are limited by efficacy in their conventional dosage forms. These findings underscore the potential and feasibility of such lymphatic drug-targeting approaches to enhance therapeutic efficacy in lupus and minimize off-target effects of the pharmaceutical drugs. SIGNIFICANCE STATEMENT: The World Health Organization estimates that there are currently 5 million humans living with some form of lupus. With limited success in lupus drug discovery, turning to effective delivery strategies with existing drug molecules, as well as those in the early stage of discovery, could lead to better clinical outcomes. After all, effective delivery strategies have been proven to improve treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Center for Convergent Bioscience and Medicine (CCBM) (K.T.B., M.A., R.G., M.N.V.R.K.), Division of Translational Science and Medicine, College of Community Health Sciences (K.T.B., M.A., R.G., M.N.V.R.K.), Alabama L…
ORCID-Profile: M Arora, R Ganugula, M N V Ravi Kumar
Förderung
- NIAID NIH HHS
Zitieren
APA
Babalola, K. T., Arora, M., Ganugula, R., Agarwal, S. K., Mohan, C., & Kumar, M. N. V. R. (2024). Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes. Pharmacological Reviews. https://doi.org/10.1124/pharmrev.123.000938
Vancouver
Babalola KT, Arora M, Ganugula R, Agarwal SK, Mohan C, Kumar MNVR. Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes. Pharmacological Reviews. 2024. doi:10.1124/pharmrev.123.000938
BibTeX
@article{Babalola2024,
author = {Babalola, K T and Arora, M and Ganugula, R and Agarwal, S K and Mohan, C and Kumar, M N V Ravi},
title = {Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes},
journal = {Pharmacological Reviews},
year = {2024},
doi = {10.1124/pharmrev.123.000938}
}
EUVIMED